Gina Mauro | Authors

Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior Therapy

May 21, 2022

Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.

Better OS Derived From Matched Sibling Donor Vs Haploidentical Transplant in R/R ALL

April 26, 2022

Transplants from a matched sibling donor were superior to haploidentical stem cell transplant in terms of 2-year survival in patients with relapsed/refractory acute lymphoblastic leukemia.

Canakinumab Combination Doesn’t Lead to Survival Improvement But Could Benefit Subgroups With Advanced NSCLC

April 14, 2022

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

ZN-c3 Yields Promising Preliminary Results in Recurrent/Advanced Uterine Serous Carcinoma

April 12, 2022

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.

Overall Survival at 2 Years With Sotorasib for KRAS G12C+ NSCLC Continues to Impress

April 11, 2022

Updated data from the phase 1/2 CodeBreaK 100 trial of sotorasib provide the longest follow-up of a KRAS G12C inhibitor in non–small cell lung cancer.

Intraperitoneal Carboplatin Plus Paclitaxel Improves PFS in Ovarian Cancer, Yet OS Results Remain Unchanged Vs IV Chemo

March 20, 2022

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.

PROpel Trial Data Show Boost in Radiographic PFS With Olaparib/Abiraterone for mCRPC

February 19, 2022

Results of the phase 3 PROpel trial presented at 2022 ASCO GU indicate a benefit of olaparib-based therapy for patients with metastatic castration-resistant prostate cancer receiving treatment in the frontline setting.

Avelumab Maintenance Yields OS Improvement of First-Line in Advanced Urothelial Cancer

February 18, 2022

Frontline avelumab plus best supportive care as maintenance showed an improvement in overall survival vs best supportive care alone in patients with advanced urothelial cancer treated after chemotherapy.

Trastuzumab Deruxtecan Reduces Risk of Death in HER2-Positive Advanced Gastric and GEJ Cancer

January 20, 2022

Patients saw an improvement in overall survival when given fam-trastuzumab deruxtecan-nxki to treat HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

Pacritinib Produced Comparable Safety Profile to Best Available Therapy for Cytopenic Myelofibrosis, Severe Thrombocytopenia

December 14, 2021

Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.